# Dexcom (DXCM) Financial Model Free Excel 3-statement financial model and company analysis for Dexcom. - Canonical: https://finamodel.com/companies/dexcom - Industry: Medical Devices - Downloadable model: Yes - Excel download: https://finamodel.com/company-models/DXCM.xlsx ## Model Purpose This model provides a comprehensive equity valuation and scenario planning tool for an analyst covering Dexcom, designed to assess how continuous glucose monitor (CGM) market penetration, international expansion, and new product launches (such as Stelo and the G7 15-day sensor) impact long-term free cash flow generation. ## Company Overview Dexcom, Inc. is a medical device company focused on the design, development, and commercialisation of continuous glucose monitoring (CGM) systems for people with diabetes. The company provides real-time glucose readings to patients and healthcare providers, replacing traditional fingerstick blood glucose testing. - **Business segments**: Dexcom disaggregates revenue primarily by Geography (U.S. at approximately 70-73% of revenue; International at 27-30%) and by Component (Sensor and other revenue at over 90%; Hardware revenue at under 10%). - **Key geographies**: United States, Europe, and an expanding presence in the Asia-Pacific region. - **Business model type**: Razor/razorblade model. The company sells durable hardware (transmitters and receivers) but generates the vast majority of its revenue from recurring, consumable sensor sales. - **Competitive position**: Dexcom operates in a global duopoly alongside Abbott (FreeStyle Libre), with Medtronic acting as a distant third player in the CGM space. - **Recent major events**: The launch of the Stelo over-the-counter CGM for Type 2 and pre-diabetes patients, the rollout of the G7 15-day sensor, and the expansion of a major new manufacturing facility in Malaysia to lower cost of goods sold. ## Revenue Deep Dive ### U.S. Revenue - **Segment name**: U.S. Revenue - **Revenue driver formula**: U.S. Patient Base x Average Annual Revenue Per User (ARPU) - **Historical growth rate**: 10-15% CAGR over the last 3 years. - **Key growth levers and headwinds**: Growth is driven by increasing Type 2 diabetes basal insulin coverage, the launch of the Stelo OTC product, and rising CGM awareness. Headwinds include channel mix shifts (moving from Durable Medical Equipment to the pharmacy channel, which carries a lower ASP) and rebate pressures. - **Pricing dynamics**: Highly contracted with pharmacy benefit managers (PBMs) and Medicare. Pricing generally faces low-single-digit annual compression, offset by volume growth. - **Revenue recognition notes**: Recognised upon shipment or delivery to distributors and patients. - **Seasonality**: Q1 is typically the weakest quarter due to the reset of high-deductible health plans in the U.S., while Q4 is the strongest as patients meet deductibles and rush to fill prescriptions. ### International Revenue - **Segment name**: International Revenue - **Revenue driver formula**: International Patient Base x International ARPU - **Historical growth rate**: 15-20% CAGR over the last 3 years. - **Key growth levers and headwinds**: Driven by geographic expansion (e.g., Dexcom ONE+ rollout in Europe) and securing national reimbursement in new countries. Headwinds include foreign exchange volatility and lower structural pricing compared to the U.S. - **Pricing dynamics**: Tender-based and government-regulated. ASPs are structurally lower than in the U.S. - **Revenue recognition notes**: Similar to the U.S., recognised upon transfer of control to distributors or direct customers. - **Seasonality**: Less pronounced than the U.S. market, though Q4 remains the strongest due to general budget flush and commercial momentum. ### Revenue by Component (Secondary Disaggregation) - **Segment names**: Sensor and other revenue; Hardware revenue. - **Dynamics**: Sensor revenue accounts for over 90% of total sales and is highly recurring. Hardware revenue (transmitters and receivers) is declining as a percentage of the total because the newer G7 system integrates the sensor and transmitter into a single wearable device, accelerating the shift entirely to "Sensor" revenue. ## Cost Structure ### Variable Costs / COGS - **Line-by-line breakdown**: Direct labour, raw materials, overhead, warranty costs, and freight. - **Gross margin range**: 61% to 65% over the last 5 years (Non-GAAP gross margin was approximately 63.5% in late 2025). - **Key input costs and commodity exposures**: Electronic components, precious metals for sensor wires, and medical-grade plastics. - **How COGS scales with revenue**: Step-function improvements. As production shifts to the highly automated Malaysia facility, the company achieves significant economies of scale, driving gross margin expansion despite ASP compression. ### Operating Expenses - **R&D**: Typically 9-11% of revenue. Covers next-generation sensor development, software/AI integration, and clinical trials. - **SG&A**: Typically 30-35% of revenue. Heavily weighted towards direct-to-consumer (DTC) television advertising, global sales force expansion, and physician education. - **Depreciation & Amortisation**: Approximately 4-5% of revenue, driven by heavy investments in automated manufacturing lines. - **Stock-Based Compensation**: Significant for Dexcom, typically running at 5-7% of revenue. - **Restructuring / one-time charges**: Infrequent, though occasionally present for facility transitions or minor business realignments. ### Margin Profile - **Gross margin**: 61-64% (stable to expanding). - **Operating margin (Non-GAAP)**: 18-23% (expanding; reached 20.8% for full-year 2025). - **Adjusted EBITDA margin**: 28-31% (guided to approximately 30-31% for 2026). - **Margin trend**: Expanding due to operating leverage on SG&A and manufacturing efficiencies, partially offset by international mix and pharmacy channel shifts. ## Balance Sheet Structure - **Total assets**: Approximately $6.0 to $7.0 billion. - **Key asset categories**: Cash, cash equivalents, and short-term marketable securities (often exceeding $2.5 billion); Inventory; Property, Plant and Equipment (PP&E). - **Goodwill & intangibles**: Relatively low (under 10% of assets) as Dexcom relies primarily on organic growth rather than transformational M&A. - **Working capital profile**: - **Days Sales Outstanding (DSO)**: 45-55 days. - **Days Inventory Outstanding (DIO)**: 90-110 days (kept high to ensure global supply chain resilience). - **Days Payable Outstanding (DPO)**: 35-45 days. - **Net working capital**: Positive, requiring investment as the company scales internationally. - **PP&E**: Heavily concentrated in manufacturing equipment and facilities in San Diego, Arizona, and Malaysia. - **Right-of-use assets**: Material but manageable, representing leased office and warehouse spaces globally. ## Capital Expenditure & Investment - **Capex as % of revenue**: 4-7% historically, peaking during the construction of the Malaysia facility. - **Maintenance vs. growth capex**: Approximately 20% maintenance, 80% growth (new automated manufacturing lines). - **Major capex programmes**: The ongoing ramp-up of the Malaysia manufacturing site to support global G7 and Stelo volume. - **Capitalised software**: Minimal compared to physical manufacturing equipment. - **M&A pattern**: Organic grower. Occasional small bolt-on acquisitions for software or data capabilities (e.g., TypeZero). ## Debt & Capital Structure - **Total debt**: Primarily consists of convertible senior notes (approximately $2.0 to $2.5 billion face value). - **Net debt**: Negative (the company holds more cash than debt). - **Debt/EBITDA ratio**: Near zero on a net basis. - **Key debt instruments**: Low-interest convertible senior notes. - **Maturity profile**: Staggered maturities typically 5-7 years out from issuance. - **Interest rate profile**: Fixed, very low cash interest expense due to the convertible nature of the debt. - **Share repurchase programme**: Active. The company announced a $750 million share repurchase programme in early 2025 to offset dilution from convertible notes and stock-based compensation. - **Dividend policy**: No dividend. Capital is returned via buybacks or reinvested in growth. ## Cash Flow Characteristics - **Operating cash flow conversion**: Strong, typically 1.2x to 1.5x of GAAP Net Income, heavily aided by the add-back of stock-based compensation and depreciation. - **Free cash flow margin**: 10-15% of revenue, expanding as the Malaysia facility capex cycle normalises. - **Major non-cash items**: Stock-based compensation, depreciation of manufacturing equipment, and amortisation of debt discount. - **Working capital cash flow impact**: A consistent use of cash due to the need to build inventory for new product launches and international expansion. - **Cash tax rate**: Lower than the statutory rate due to R&D tax credits and excess tax benefits from stock-based compensation. ## Sheet Structure 1. **Assumptions**: Hardcoded drivers for U.S. and International revenue growth, margins, working capital days, and capex. 2. **Revenue Build**: Disaggregation of revenue by Geography (U.S. vs International) and Component (Sensor vs Hardware), driven by volume and ASP assumptions. 3. **Income Statement**: GAAP and Non-GAAP views, explicitly breaking out SBC and one-time charges to bridge to Adjusted EBITDA. 4. **Balance Sheet**: Standard asset and liability line items mirroring the 10-K, with specific breakouts for convertible debt and inventory. 5. **Cash Flow Statement**: Indirect method starting from Net Income, highlighting SBC, working capital changes, and capex. 6. **Debt & Interest Schedule**: Tracking convertible note balances, amortisation of debt discount, and cash interest paid. 7. **Working Capital & Capex**: Schedules for DSO, DIO, DPO, and PP&E roll-forward. 8. **DCF Valuation**: Unlevered free cash flow build, WACC calculation, and terminal value using the perpetuity growth method. ## Key Financial Relationships 1. `U.S. Revenue = Prior Year U.S. Revenue x (1 + U.S. Revenue Growth Rate)` 2. `International Revenue = Prior Year International Revenue x (1 + International Revenue Growth Rate)` 3. `Total Revenue = U.S. Revenue + International Revenue` 4. `Sensor and Other Revenue = Total Revenue x Sensor Mix % (projected at >90%)` 5. `Hardware Revenue = Total Revenue x Hardware Mix %` 6. `Cost of Sales = Total Revenue x (1 - Gross Margin %)` 7. `R&D Expense = Total Revenue x R&D % of Revenue` 8. `SG&A Expense = Total Revenue x SG&A % of Revenue` 9. `Non-GAAP Operating Income = Total Revenue - Cost of Sales - R&D Expense - SG&A Expense (excluding SBC)` 10. `Adjusted EBITDA = Non-GAAP Operating Income + Depreciation & Amortisation` 11. `Accounts Receivable = (Total Revenue / 365) x DSO` 12. `Inventory = (Cost of Sales / 365) x DIO` 13. `Free Cash Flow = Cash from Operations - Capital Expenditures` ## Cross-Sheet Dependencies - The **Assumptions** sheet feeds the **Revenue Build**, **Income Statement**, and **Working Capital** sheets. - The **Revenue Build** dictates the top line of the **Income Statement** and drives the Accounts Receivable balance on the **Balance Sheet**. - The **Income Statement** generates Net Income, which is the starting point for the **Cash Flow Statement**. - The **Working Capital** sheet calculates changes in operating assets and liabilities, feeding directly into the **Cash Flow Statement**. - The **Cash Flow Statement** determines the ending cash balance, which links back to the **Balance Sheet**. - A circularity exists if interest income on cash balances is modelled, as cash depends on net income, which depends on interest income. This should be managed with a circularity toggle. ## Sign Convention - Revenue and Assets are positive. - Expenses (COGS, R&D, SG&A) are modelled as positive numbers and subtracted in subtotals. - On the Cash Flow Statement, cash inflows are positive, and cash outflows (including capex and working capital increases) are negative. - Debt balances are positive; principal repayments are negative. ## Things Most Likely to Go Wrong - **Ignoring the channel mix shift**: Assuming constant ASPs will overstate revenue. The shift to the pharmacy channel lowers ASPs but increases volume; the model must reflect this dynamic. - **Mishandling Stock-Based Compensation**: Dexcom has high SBC. Failing to separate GAAP from Non-GAAP operating margins will result in a misunderstanding of the company's true cash generation and valuation multiples. - **Overestimating Hardware Revenue**: As the G7 system integrates the transmitter into the sensor, standalone hardware revenue will structurally decline. Projecting historical hardware growth rates will break the model. - **Mismodelling Q1 Seasonality**: Extrapolating Q4 revenue into Q1 will drastically overstate full-year revenue due to U.S. deductible resets. - **Ignoring foreign exchange**: International revenue is highly sensitive to currency fluctuations. The model should ideally have a constant-currency toggle or explicitly state FX assumptions. - **Underestimating Inventory needs**: Dexcom carries high inventory to support global launches. Assuming a standard 30-day DIO will artificially inflate modelled cash flow. - **Double-counting convertible debt dilution**: The model must properly handle the convertible notes using the treasury stock method if the stock price exceeds the conversion price. - **Misaligning Capex and Depreciation**: The massive Malaysia facility investment means depreciation will step up significantly; keeping D&A flat as a percentage of revenue will understate expenses. ## Validation Checks - "Non-GAAP Gross margin should remain in the 61-65% band; flag if outside this range." - "Non-GAAP Operating margin should be between 20-23% based on recent management guidance." - "Adjusted EBITDA margin should approximate 30-31% for 2026 and beyond." - "Capex as a % of revenue should normalise between 4-6%." - "Q1 U.S. Revenue should sequentially decline or remain flat compared to Q4 of the prior year." - "Sensor revenue must account for >90% of Total Revenue." - "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every period." - "Free Cash Flow conversion (FCF / Non-GAAP Net Income) should remain positive and trend towards 70-80%." ## Key Assumptions (Default Values) | Assumption | Default Value | Unit | Rationale | |---|---|---|---| | U.S. Revenue Growth | 11.0 | % | Based on 2025/2026 guidance and market penetration rates. | | International Revenue Growth | 15.0 | % | Based on recent historical performance and Dexcom ONE+ rollout. | | Sensor & Other Mix | 94.0 | % | Reflects the transition to G7, which eliminates separate transmitter sales. | | Non-GAAP Gross Margin | 63.5 | % | Aligns with Q4 2025 actuals and 2026 guidance. | | R&D as % of Revenue | 10.0 | % | Historical average required to maintain product pipeline. | | SG&A as % of Revenue | 31.0 | % | Reflects operating leverage while maintaining DTC advertising spend. | | Stock-Based Comp as % of Rev | 6.0 | % | Historical average for the company. | | DSO (Days Sales Outstanding) | 50 | Days | Based on historical U.S. pharmacy and international tender payment cycles. | | DIO (Days Inventory Outstanding)| 100 | Days | Required to maintain global supply chain stability. | | DPO (Days Payable Outstanding) | 40 | Days | Historical average. | | Capex as % of Revenue | 5.0 | % | Normalised run-rate following the Malaysia facility build-out. | | Effective Tax Rate | 16.0 | % | Blended global rate factoring in R&D credits. | | WACC | 8.5 | % | Standard discount rate for a large-cap, high-growth medtech company. | | Terminal Growth Rate | 3.0 | % | Long-term global diabetes market growth assumption. | ## Data Sources & Benchmarks - **Filings**: SEC EDGAR (Dexcom 10-K, 10-Q, 8-K) and the Dexcom Investor Relations website (investors.dexcom.com). - **Key Peers**: Abbott Laboratories (ABT), Medtronic (MDT), Insulet (PODD), Tandem Diabetes Care (TNDM). - **Industry Data**: International Diabetes Federation (IDF) Atlas for global diabetes prevalence; IQVIA for U.S. pharmacy prescription volume data. - **Consensus Estimates**: FactSet or Bloomberg for forward-looking analyst consensus on revenue and EBITDA margins. ## Sources - Dexcom Q4 and Full Year 2025 Financial Results Press Release (February 2026) - Dexcom Q3 2025 Financial Results Press Release (October 2025) - Dexcom Q2 2025 Financial Results Press Release (July 2025) - Dexcom Q4 and Full Year 2024 Financial Results Press Release (February 2025) - Dexcom 2024 Annual Report and Form 10-K - Dexcom Investor Relations Presentations (2025-2026) --- ## Frequently asked questions ### What does Dexcom do and what is its primary business model? Dexcom, Inc. develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes, providing real-time glucose readings. Its business model is primarily "razor/razorblade," where durable hardware sales are supplemented by the vast majority of revenue coming from recurring consumable sensor sales. ### What are the main drivers of Dexcom's revenue growth? Dexcom's revenue growth is driven by increasing CGM market penetration, international expansion into regions like Asia-Pacific, and new product launches such as the Stelo over-the-counter CGM and the G7 15-day sensor. Sensor and other revenue accounts for over 90% of total revenue, indicating the importance of recurring sales. ### What is Dexcom's historical capital expenditure as a percentage of revenue? Historically, Dexcom's capital expenditure has ranged from 4-7% of revenue, with peaks during significant facility constructions like the Malaysia manufacturing site. Approximately 80% of this capex is allocated to growth initiatives, such as new automated manufacturing lines, rather than just maintenance. ### What are the key cost assumptions in a financial model for Dexcom? Key cost assumptions include COGS at approximately 34.78% of revenue, R&D at about 17.79% of revenue, and SGA at roughly 33.50% of revenue. These percentages reflect the company's investment in product development and market expansion. ### How does Dexcom's working capital profile impact its free cash flow generation? Dexcom maintains a positive net working capital, which requires ongoing investment as the company expands globally. Its Days Inventory Outstanding (DIO) is kept high at 90-110 days to ensure global supply chain resilience, influencing its cash conversion cycle. ### Can I download an Excel financial model for Dexcom (DXCM) and what is its forecast horizon? Yes, an Excel financial model for Dexcom (DXCM) is available for download, providing a comprehensive equity valuation and scenario planning tool. The model offers a forecast horizon from FY2026 through FY2030. [Interactive forecast calculator](https://finamodel.com/companies/dexcom/forecast)